Early studies utilized intracerebroventricular injections to show that exogenous modulation of GLP-1 action could dose dependently increase (through antagonism)(Meeran et al., 1999) or decrease (through agonism)(Donahey et al., 1998
Pribenszky, C
Kidney and liver safety The kidney and liver data actually presents one of the most interesting differences between the two medications
Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint
Counteracting Hormone-Related Weight Gain A common side effect of aromatase inhibitors like letrozole is weight gain or difficulty losing weight
(10) M Backmund, K Meyer, H B Rothenhaeusler, and M Soyka (1998) Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial Journal of Clinical Psychopharmacology, 1998 Jun, Volume 18 (Issue 3), Pages 257-8